Kinship Partners, Inc. v. Embark Veterinary, Inc.

CourtDistrict Court, D. Oregon
DecidedJanuary 3, 2022
Docket3:21-cv-01631
StatusUnknown

This text of Kinship Partners, Inc. v. Embark Veterinary, Inc. (Kinship Partners, Inc. v. Embark Veterinary, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kinship Partners, Inc. v. Embark Veterinary, Inc., (D. Or. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF OREGON

KINSHIP PARTNERS, INC., No. 3:21-cv-01631-HZ

Plaintiff, OPINION & ORDER

v.

EMBARK VETERINARY, INC. and ROBIN P. SMITH,

Defendants.

Kjersten H. Turpen K&L Gates LLP One SW Columbia Street, Suite 1900 Portland, OR 97204

Jonathan Stoler Adam Pekor Lindsay C. Stone Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, NY 10112

Attorneys for Plaintiff Peter Hawkes Edward A. Piper Angeli Law Group LLC 121 SW Morrison Street, Suite 400 Portland, OR 97204

Jeffrey M. Edelson Markowitz Herbold PC 1455 SW Broadway, Suite 1900 Portland, OR 97201

Attorneys for Defendants

HERNÁNDEZ, District Judge: Plaintiff Kinship Partners, Inc. (“Kinship”) seeks an injunction that prohibits Defendants Robin P. Smith (“Smith”) and Embark Veterinary, Inc. (“Embark”) “from possessing, using, disclosing, or benefitting from . . . Kinship’s trade secrets and confidential and proprietary information in any manner.” Pl. Mot. 1, ECF 2. Plaintiff also seeks to enjoin Smith from working for Embark for a period of 12 months. Id. Smith, who previously worked at Kinship, resigned from his position on November 1, 2021 and had intended to begin employment with Embark on November 15, 2021. Ex. 2; Smith Decl. ¶ 16. The Court issued a Temporary Restraining Order (“TRO”) on November 10, 2021 and held an evidentiary hearing on Plaintiff’s Motion for a Preliminary Injunction on November 22, 2021. For the reasons stated below, the Court denies Plaintiff’s motion and dissolves the TRO. BACKGROUND Kinship and Embark, as the two leading providers of canine DNA testing services worldwide, are head-to-head competitors. Compl. ¶ 2, ECF 1. Defendant Smith is the former Head of Product for Kinship’s Wisdom brand, which offers customers pet DNA testing and related services. Ex. 6; Compl. ¶ 17. Smith was hired by Kinship on December 17, 2020 “to lead all aspects of the product development, user experience, and visual design of Wisdom, as well as to devise and lead the brand’s overall business strategy. Yoo Decl. ¶ 11, ECF 2-1. Smith had previously worked for Kinship’s parent company, Mars Petcare, US (“Mars”) beginning July 2019. Compl. ¶ 3. Smith was an “at-will” employee at Kinship, which means either Smith or Kinship could terminate the employment relationship at any time. Ex. 6, ¶ 7. Kinship requests,

but does not require, that employees give two weeks’ notice upon resignation. Ex. 24D. On December 17, 2020, when he was hired to his recent position at Kinship, Smith signed a Proprietary Information and Inventions Agreement (“IP Agreement”) and a Confidential Information and Invention Assignment Agreement. (“Confidentiality Agreement”). Yoo Decl. ¶ 15; Ex. 24C. Paragraph 5(a) of the IP Agreement and paragraph 2(a) of the Confidentiality Agreement contain identical language as follows: Confidential Information. (a) Protection of Information. I agree, at all times during the term of the [employment] Relationship and thereafter, to hold in strictest confidence, and not to use, except for the benefit of the Company to the extent necessary to perform my obligations to the Company under the Relationship, and not to disclose to any person, firm, corporation or other entity, without written authorization from the Company in each instance, any Confidential Information (as defined below) that I obtain, access or create during the term of the Relationship, whether or not during working hours, until such Confidential Information becomes publicly and widely known and made generally available through no wrongful act of mine or of others who were under confidentiality obligations as to the item or items involved. I further agree not to make copies of such Confidential Information except as authorized by the Company.

Ex. 24C. Paragraph 4 of the Confidentiality Agreement states in part:

I agree that, at the time of termination of the [employment] Relationship, I will deliver to the Company (and will not keep in my possession, recreate or deliver to anyone else) any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, materials, flow charts, equipment, other documents or property, or reproductions of any of the aforementioned items developed by me pursuant to the Relationship or otherwise belonging to the Company, its successors or assigns.

Id. Smith also signed and received a copy of Kinship’s Associate Handbook, which notifies employees that they must “keep all such confidential and proprietary information in confidence.” Ex. 24D. All Kinship employees sign an IP Agreement, a Confidentiality Agreement, and the Associate Handbook. Some high-level Kinship employees are also required to sign noncompetition agreements as a condition of employment. Smith was not asked and did not sign a noncompetition agreement when he was first hired by Mars in July 2019 or when was hired by Kinship in December 2020. Smith Decl. ¶ 5. On October 1, 2021, Embark CEO Ryan Boyko sent Smith a message through LinkedIn, inviting him to discuss the possibility of employment at Embark. Id. at ¶ 1. Smith claims that he was initially not interested because he did not want to work for Kinship’s competitor. Id. at ¶ 3. But Smith became interested in the opportunity when he learned that Embark planned to move in a different direction than Kinship. Id. Embark specifically wanted “to get more into research and potentially drug discovery.” Id. On October 15, after a series of scheduling emails, Smith met with Boyko over video chat. Id. at ¶ 5. Over the next two weeks, Smith met with several other Embark representatives to discuss the possibility of employment. Id. Smith accepted an offer of employment with Embark on October 29 and signed a formal offer letter on October 31. Id. at ¶ 6; Ex. 2. Embark’s onboarding document for Smith states: “you will focus on supporting and improving the Research & Development arm of Embark (internally called “Branch 2”)[.] . . .

your work will not be focused on our existing product’s strategy, sales or NPS. Success in your role will be measured on the rate and value of new discovery[.]” Ex. 42. In the months leading up to his resignation from Kinship, Smith continued his work as Head of Product for the Wisdom brand. In September 2021, Smith gave a presentation to Kinship’s most senior executives entitled “Wisdom 2022+ Product & Innovation” that described the strategic vision for the Wisdom brand. Compl. ¶40. On October 27, 2021, Smith again presented the Wisdom brand’s product roadmap and strategic vision to Kinship’s senior directors. Id. at 41. On November 1, 2021, Smith, who was working remotely from home, sent a Letter of

Resignation by email to three senior leaders at Kinship, indicating that his last day would be November 12, 2021, and that he intended to join Embark in a role focusing on “research and discovery.” Yoo Decl. ¶58, 61; Ex. 19. In his resignation email, Smith stated: I also plan to cease business activity today until directed on how you’d like to proceed – please advise. The only company property in my possession is the laptop I’ve been using over the past few years. I’m happy to bring this into the office or mail as directed.

Ex. 19. Within two hours of the resignation email, Smith received a call from Luis Alvarado, Kinship’s head of human relations, who told Smith that Kinship was “accelerating” his resignation to be effective immediately. Smith Decl. ¶ 9. Kinship did not conduct an exit interview with Smith. Id. at ¶10. On the day of Smith’s resignation, Kinship conducted a “forensic review of his network activity.” Compl. ¶ 43; Yoo Decl. ¶ 68.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Weinberger v. Romero-Barcelo
456 U.S. 305 (Supreme Court, 1982)
Samuel Lopez v. Janice Brewer
680 F.3d 1068 (Ninth Circuit, 2012)
Payment Alliance International, Inc. v. Ferreira
530 F. Supp. 2d 477 (S.D. New York, 2007)
Stormans, Inc. v. Selecky
586 F.3d 1109 (Ninth Circuit, 2009)
The Lands Council v. McNair
537 F.3d 981 (Ninth Circuit, 2008)
Bayer Corp. v. Roche Molecular Systems, Inc.
72 F. Supp. 2d 1111 (N.D. California, 1999)
Ferring B.V. v. Allergan, Inc.
4 F. Supp. 3d 612 (S.D. New York, 2014)
Alliance for Wild Rockies v. Cottrell
632 F.3d 1127 (Ninth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Kinship Partners, Inc. v. Embark Veterinary, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kinship-partners-inc-v-embark-veterinary-inc-ord-2022.